Our vision is to reshape diagnostics for a healthier and more sustainable future.
‍

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering and product management efforts, driving the Company’s commercial, partnership and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industry. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.

Angie Aquino-Sales serves as Senior Director of People & Culture at Alveo Technologies, where she is focused on human resources strategic planning and organizational design, building HR functions, and designing talent programs for leader and employee development.

Prior to joining Alveo, Angie served at Prologis as a Senior Human Resources Business Partner, at OptiScan Biomedical as Head of HR, and at Tripping.com as Director of HR. Angie has experience working in start-ups and small businesses in a variety of industries. She has held related roles in large organizations including Kaiser Permanente, Blue Shield of California, and McKesson.

Helen Belcastro brings over 20 years of experience in cross-functional program and project management in the medical device and biotechnology arenas to her role as Vice President, Portfolio Planning and Program Management at Alveo Technologies. Previously, she applied her program management leadership to the digital transformation of molecular diagnostics at Atonarp, helping to improve clinical outcomes and enhance the patient experience. Prior to Atonarp, Helen built her extensive experience managing complex product development projects at all stages from concept through product release through her work at companies including ViewRay, Inc., VytronUS, Intuitive Surgical, Novartis Vaccines and Diagnostics, and Boston Scientific.

Lisa Charter is an accomplished leader in the field of regulatory affairs, leveraging over 25 years of expertise across various domains including therapeutic drug monitoring, toxicology, anatomical pathology, hematology, allergy diagnostics, and direct-to-consumer genetics. Currently serving as Vice President of Regulatory Affairs at Alveo Technologies, Lisa plays a pivotal role in steering regulatory strategies and ensuring regulatory compliance.

With a rich background in medical device regulation, Lisa's journey encompasses pivotal roles at esteemed organizations such as Atonarp, 23andMe, Hitachi Chemical Diagnostics, and ThermoFisher Scientific. Notably, at 23andMe, she spearheaded groundbreaking initiatives securing multiple first-of-their-kind de novo authorizations and 510(k) clearances for direct-to-consumer genetic tests.

Beyond her professional commitments, Lisa remains deeply engaged in advancing regulatory standards within the industry. Her dedication extends to her current position on the Board of Directors for the Association of Medical Diagnostics Manufacturers (AMDM), where she actively contributes to shaping educational resources for regulatory professionals, facilitating knowledge exchange on submission and compliance requirements.

John, a seasoned Manufacturing Operations Leader, spans small startups to industry giants like Flextronics, Mars Petcare, and Tesla Motors, showcasing expertise in management, manufacturing, and logistics. Excelling in building capabilities, crafting efficient supply chains, and fostering effective organizations, John's hands-on approach and strategic mindset have been instrumental in both internal and external manufacturing. His proven track record solidifies him as a valuable and respected leader in manufacturing operations, with a career defined by impactful contributions to diverse enterprises.

Mariana is a forward-thinking business leader and Ph.D. Scientist with 20 years of successful product development and launches within the In Vitro Diagnostics industry. She brings to Alveo her experience from working for both - Fortune 100 companies and mid-size medical device organizations. Mariana has experience in all aspects of Immunoassay and Molecular product development and U.S. FDA and IVD submissions and in post-acquisition Integration Management.  She has a demonstrated record for excellence in R&D Operational leadership driving team’s performance and building up and leading PMO organizations with projects at a scale of up to $500M.

Mariana holds a Ph. D. in Molecular Biology from the Ruhr University Bochum, Germany and a M.S. in Organic Chemistry from the University of Sofia, Bulgaria.

Dr. Anand Hindupur brings to Alveo more than 15 years of experience in the vitro diagnostics and medical devices industry. Previously, Anand held senior positions in research and development positions designing and developing molecular products for the detection of infectious microorganisms, including fungus, with publicly traded and private companiesdesigning and developing molecular products for the detection of infectious microorganisms, including fungus, with publicly traded and private companies including including and Meridian Biosciences and MiraVista Diagnostics. He has led 10 molecular diagnostic product development projects from product concept through U.S. regulatory clearances.

Raj Limaye brings over 30 years of software engineering experience in IVD, digital health, and medical devices to his role as Vice President of Software Engineering at Alveo Technologies. Previously, Raj managed software engineering efforts at Thermo Fisher Scientific, helping improve COVID-19 diagnostics. Prior to Thermo Fisher, Raj spearheaded digital health and medical device software development at companies including Flextronics, Parexel, United Health, Varian Medical, and a few start-ups, driving technical vision, fostering high-performing teams, and delivering impactful solutions aligned with business objectives. Raj holds a BS degree in Electronics & Telecommunication Engineering from India and an MBA from Santa Clara University.

Mary McFillin is a senior global product marketing manager with extensive experience in the point-of-care diagnostics industry, leading strategy, development and support of in vitro diagnostics medical devices throughout the product life cycle. As a senior product management executive, Mary leads Alveo’s strategic marketing and target market development. She joins Alveo from Thermo Fisher Scientific, Rapid Diagnostic Solutions, where she served as Senior Manager of Product Management. Previously, she held similar positions for Abbott Laboratories and Alere, Inc.

Younes joined Alveo with over 25 years of experience in product design, development, manufacturing, technology leadership, team building, operations and engineering management. His product development expertise spans a broad range of products including semiconductor, medical, telecom, networking, computing, consumer, automobile, solar, LED lighting, gaming, multimedia, industrial, and power electronic products. His extensive experience comes from working at both startup companies, as well as large contract manufacturers such as Flextronics and Sanmina. He came to Alveo from another startup company Atonarp where he led product development from early engineering and design phase all the way through final production. Younes is also very passionate about teaching and has been an adjunct faculty at San Jose State University for over 24 years. Younes received his Ph.D. in Mechanical Engineering with a minor in Aeronautics and Astronautics from Stanford University. He has eight granted patent applications, and authored a book titled “Heat Transfer; Thermal Management of Electronics”.

Dr. Michael Thompson is personally passionate about the application of science to improve the human condition and the diverse systems that support it.

Before joining Alveo, Dr. Thompson founded Kairos Ag, a consultancy specializing in agricultural genomics and business development. He previously served as Vice President of Partner Development at Benson Hill, Director of Global Sales and Market Development for Illumina’s Agriculture business, and Manager of the DNA Technologies division at BioDiagnostics, Inc. Earlier in his career, he held multiple leadership roles in research and technology development at Monsanto and worked as a postdoctoral research associate at the University of Arizona, Tucson.

Dr. Thompson holds bachelor's degrees in Chemistry and Biology from the University of Colorado, Boulder, and a Ph.D. in Plant Molecular Biology from the University of Minnesota.

For 40 years, Michael Marks has successfully led and transformed technology companies. He is a founding managing partner at Celesta Capital, where he co-leads the firm. From 2007 to 2019, he was a founding partner at Riverwood Capital Management, a private equity fund specializing in rapidly growing private companies in North America and emerging markets. He was a partner and senior advisor at Kohlberg Kravis Roberts & Co (KKR) in 2006 and 2007. Before KKR, he spent 13 years as Chairman and CEO of Flextronics International Ltd and built the company into one of the largest technology companies in the world.

Chris Lucas, Founder and Managing Director, formed Black Diamond Ventures to provide the individual investor the ability to invest alongside first-tier venture capital firms and institutional investors in privately-held companies. For over thirty-five years, Chris has raised capital, held board positions and managed several of the portfolio companies through successful IPO’s or acquisitions, including DexCom (DXCM), DivX Networks (DivX), Khimetrics (Acquired by SAP) and Forece10 Network (Acquired by Dell). Chris currently serves on the board of several private companies and foundations, including LiquidSpace, Tela Innovations, NEI Treatment Systems, Capella Photonics and The Lucas Brothers Foundation.

Prior to Black Diamond Ventures, Chris held executive positions for over 20 years, in several venture-backed or privately held companies, including Global One Distribution and Merchandising, and Peripheral Systems. Through his venture partnerships and family relationships, Chris was previously an investor in Advanced Fibre Communications (AFC), Cadence Design Systems (CDNS), Cerus Corporation (CERS), Coulter Pharmaceuticals (CLTR), Infinera Corporation (INFN), Macromedia (MACR), Quantum Health (QNTM) and Vixel Corporation (VIXL).

Chris received his MBA in Finance from the University of Southern California and a Bachelor of Science, magna cum laude, in Mechanical Engineering from the University of California Los Angeles.

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

Dr. Rothman is an internationally renowned scientist. He was awarded the 2013 Nobel Prize in medicine and has received numerous other honors including the Lasker Basic Research Award. Dr. Rothman is also a biopharmaceutical company founder, life science industry executive, and prestigious academic leader. Dr. Rothman served as chief scientist and executive committee member at GE Healthcare, a $15B unit of General Electric Corporation. Prior to the acquisition of Amersham Biosciences PLC by GE Healthcare, Dr. Rothman served as chief scientist at Amersham. His distinguished academic career includes endowed chairs at Memorial Sloan-Kettering Cancer Center where he served as vice-chair of the Sloan-Kettering Institute; Columbia University’s College of Physicians and Surgeons; and Yale University, where he is currently professor and chair of cell biology and executive director for high throughput cell biology. He is a member of the National Academy of Sciences, a member of the Institute of Medicine of the National Academy of Sciences, and fellow of the American Academy of Arts and Sciences.